Periscope Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Periscope Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-69,604	Closed	-$692K	–	981
2021 Q3	$692K	Sell	69,604 -5,196	-7%	-$51.6K	0.02%	577
2021 Q2	$744K	Sell	74,800 -25,200	-25%	-$254K	0.02%	526
2021 Q1	$996K	Hold	100,000	–	–	0.04%	412
2020 Q4	$1.08M	Buy	+100,000	New	+$1.03M	0.06%	280

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Periscope Capital's STLN Position: Q4 2021 in Review

Periscope Capital sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 69,604 shares — an estimated $692K sold.

Periscope Capital first reported a position in STLN in Q4 2020 and held it in 4 quarters. The position peaked at $1.08M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

Periscope Capital reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Periscope Capital sold 69,604 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $692K.
Periscope Capital first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Periscope Capital's Starling Oncology Institute, Inc. Common Stock position peaked at $1.08M in Q4 2020.
21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on Periscope Capital's 13F filing for Q4 2021, filed 14 Feb 2022.